PD
AARD

Point72 (DIFC)’s Aardvark Therapeutics AARD Stock Holding History

Point72 (DIFC)’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-12,797
Closed -$96.1K – 2188
2025
Q1 		$96.1K Buy
+12,797
New +$144K ﹤0.01% 1076

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Point72 (DIFC)'s AARD Position: Q2 2025 in Review

Point72 (DIFC) sold out of Aardvark Therapeutics (AARD) in Q2 2025, closing a stake of 12,797 shares — an estimated $96.1K sold.

Point72 (DIFC) first reported a position in AARD in Q1 2025 and held it in 1 quarter. The position peaked at $96.1K in Q1 2025. 35 funds tracked by Wall St. Rank hold AARD as of Q2 2025.

  • Point72 (DIFC) reported no remaining Aardvark Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Point72 (DIFC) sold 12,797 Aardvark Therapeutics shares in Q2 2025, an estimated $96.1K.
  • Point72 (DIFC) first reported a position in Aardvark Therapeutics in Q1 2025 and held it in 1 quarter.
  • Point72 (DIFC)'s Aardvark Therapeutics position peaked at $96.1K in Q1 2025.
  • 35 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q2 2025.

Based on Point72 (DIFC)'s 13F filing for Q2 2025, filed 14 Aug 2025.